Mariner
CPRX

Mariner’s Catalyst Pharmaceutical CPRX Stock Holding History

Mariner’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$722K Buy
+22,969
New +$678K ﹤0.01% 2199
2026
Q1 		– Sell
-14,935
Closed -$349K – 3615
2025
Q4 		$349K Buy
+14,935
New +$333K ﹤0.01% 2720

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mariner's CPRX Position: Q2 2026 in Review

Mariner opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 22,969 shares worth $722K. The stake represents ﹤0.01% of the portfolio and ranks #2199 among its holdings. This is a return to the name: Mariner previously reported a position in CPRX as recently as Q4 2025.

Mariner first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Mariner held 22,969 shares of Catalyst Pharmaceutical worth $722K as of Q2 2026.
  • Catalyst Pharmaceutical was a new Mariner position in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2199 holding.
  • Mariner first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.